Breakthrough Tips for Innovators from Former FDA Program Lead

article image

Often-overlooked regulatory and related reimbursement considerations for device companies pursuing the popular Breakthrough Device pathway from John Doucet, former Policy Lead for the Breakthrough Device Program at FDA.

John Doucet, PhD, views the popular FDA Breakthrough Device Program (BDP) from a unique perspective: he led the program from 2018 through August of this year, where he had a hand in the granting or denial of more than 200 Breakthrough requests. Doucet’s first-hand experience offers valuable insights for device companies that may be pursuing this regulatory pathway.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: